SCHEMBL30567

SCHEMBL30567

Cc1nncn1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30566 0.69
SCHEMBL16067296 0.69
SCHEMBL22043516 0.69
SCHEMBL14020814 0.66 PTK2 (0.45)
SCHEMBL21240975 0.65
SCHEMBL22761167 0.64
SCHEMBL61170 0.63 ALDH1A1 (0.38)
SCHEMBL21303136 0.63 MEN1 (0.45)
SCHEMBL21536857 0.62 PGR (0.32)
SCHEMBL20982448 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 443 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12503439-B2 Heteroaryl compounds for the treatment of pain VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-12-23 US disclosed
US-20250195480-A1 MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS Fulcrum Therapeutics, Inc. 2025-06-19 US disclosed
US-12109198-B2 Macrocyclic azolopyridine derivatives as EED and PRC2 modulators Fulcrum Therapeutics, Inc. (US) 2024-10-08 US disclosed
US-12023319-B2 Carboxylic acid aromatic amides BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2024-07-02 US disclosed
WO-2024137674-A2 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. (US) 2024-06-27 WO disclosed
WO-2024102455-A1 NON-COVALENT INHIBITORS OF CORONAVIRUS MAIN PROTEASE EMORY UNIVERSITY (US) 2024-05-16 WO disclosed
US-20240140943-A1 COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 VANDERBILT UNIVERSITY 2024-05-02 US disclosed
US-20240139163-A1 MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS Fulcrum Therapeutics, Inc. 2024-05-02 US disclosed
CN-114144230-B Macrocyclic azolopyridine derivatives as EED and PRC2 modulators 弗尔康医疗公司 2024-04-23 CN disclosed
US-20240069439-A1 LITHOGRAPHIC PRINTING PLATE PRECURSOR AND METHOD OF USE EASTMAN KODAK COMPANY 2024-02-29 US disclosed
US-20060167246-A1 Thienopyrrole compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2006-07-27 US disclosed
WO-2004064842-A1 AMIDE AND ESTER MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-08-05 WO disclosed
WO-2004014384-A2 CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed
WO-2004014892-A1 MONOCYCLIC DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed
WO-1995034542-A1 TRIAZOLE COMPOUND AND ANTIFUNGAL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT TOKYO TANABE COMPANY LIMITED (JP) 1995-12-21 WO disclosed
US-5389663-A Fungicides TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1995-02-14 US disclosed
EP-0510700-A2 Azole compounds, their production and use TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1992-10-28 EP disclosed
EP-0034924-B1 PROCESS FOR PREPARING 3-IODOMETHYL CEPHALOSPORINS ELI LILLY AND COMPANY (US) 1984-07-04 EP disclosed
EP-0034924-A2 Process for preparing 3-iodomethyl cephalosporins ELI LILLY AND COMPANY (US) 1981-09-02 EP disclosed
US-4266049-A Process for 3-iodomethyl cephalosporins ELI LILLY AND COMPANY (US) 1981-05-05 US disclosed